<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825212</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 15-2282</org_study_id>
    <secondary_id>IN-US-337-1716</secondary_id>
    <nct_id>NCT02825212</nct_id>
  </id_info>
  <brief_title>Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia</brief_title>
  <official_title>Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      10 patients with chronic genotype 1 HCV infection and mixed cryoglobulinemia will be treated&#xD;
      with Ledipasvir/Sofosbuvir 90mg/400 mg FDC once daily for 12 weeks (naïve subjects or&#xD;
      non-cirrhotic treatment experienced subjects) or 24 weeks (treatment experienced subjects&#xD;
      with cirrhosis).&#xD;
&#xD;
      The researchers anticipate that approximately 20% of subjects may have cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of extrahepatic disease manifestations of HCV has largely paralleled that of&#xD;
      hepatic disease. Interferon was reported to have efficacy for MC even before linkage of the&#xD;
      syndrome to HCV in 1989, and successful combination therapy with ribavirin was found to&#xD;
      eliminate virus and lead to the resolution of immunologic abnormalities associated with&#xD;
      extrahepatic disease. In addition, ~75% of HCV-associated indolent asymptomatic&#xD;
      lymphoproliferative diseases remit with successful antiviral therapy. However, in many&#xD;
      instances, MC (notably cutaneous vasculitis) will relapse with recurrence of virus, and may&#xD;
      occasionally persist even after clearance. In particular, side effects of Interferon alpha,&#xD;
      including the uncovering of frank autoimmune disease, theoretically may mitigate response of&#xD;
      extrahepatic disease to treatment. Peg-interferon increased the response rate of MC, and&#xD;
      decreased the duration of treatment, but side effects remained problematic.&#xD;
&#xD;
      An alternative approach to the treatment of MC has been the use of immunomodulatory agents.&#xD;
      In particular, B-cell expansion in peripheral blood and in lymphoid follicles in the liver&#xD;
      prevalent amongst HCV-infected persons provided a rationale for the use of depletion as a&#xD;
      therapeutic strategy. Rituximab (anti-CD20) monotherapy has been used mostly for treatment&#xD;
      failures/intolerance or in the setting NHL, and has yielded response rates in the setting of&#xD;
      involvement of skin (73%); MPGN (70%); joint (53%); and nerve (36%). However, this monoclonal&#xD;
      antibody (MAb) has the potential to form immune-complexes with mixed cryoglobulin RF and&#xD;
      cause clinical vasculitis in patients with high cryocrits, and may raise the HCV RNA level in&#xD;
      rare patients, causing cytotoxicity. Following Rituximab with Peg-IFN plus ribavirin achieved&#xD;
      greater than a 60% complete response (CR) in patients resistant to combination treatment&#xD;
      alone. Other approaches include the use of Aldesleukin, an inducer of regulatory T-cell&#xD;
      activity, MAbs targeted to specific B-cell subsets or costimulatory signal molecules (e.g.&#xD;
      BAFF) or agents inhibiting the interaction of HCV core antigen with C1q in cryoprecipitates&#xD;
      via the receptor for the globular domain of C1q (gC1qR).&#xD;
&#xD;
      The development of low molecular weight inhibitors of the non-structural proteins (NSPs)&#xD;
      elaborated by HCV, in particular 5A, 5B nucleoside and non-nucleoside polymerase inhibitors,&#xD;
      and inhibitors of 3/4A serine proteases; to selectively inhibit HCV replication has raised&#xD;
      the prospect of &quot;all-oral&quot; treatment for both hepatic and extrahepatic manifestations of&#xD;
      disease. However, the use of first generation direct-acting antiviral agents (Telaprevir® and&#xD;
      Boceprevir® linear NS3/4A protease inhibitors) was limited by frequent escape mutants,&#xD;
      efficacy restricted to genotype-1, need to retain protocols including PegIFN and ribavirin,&#xD;
      potential for significant drug interactions, and serious side effects. In a trial of&#xD;
      combination therapy including Telaprevir® for 13 patients with MC, all had significant AEs,&#xD;
      including asthenia (92%), anemia (84%), neutropenia and bacterial infection (54%). Approval&#xD;
      of an uridine nucleoside analogue that selectively inhibits HCV NS5B RNA-dependent RNA&#xD;
      polymerase (Sofosbuvir) by the FDA late 2013 has led to proof-of-concept trials in which&#xD;
      combination all-oral therapy has proven effective for both genotype 1 and other genotypes,&#xD;
      with a number of other regimens under development. In particular, the combination of&#xD;
      Sobosbuvir (SOF) and Ledipasvir (LDV) has been reported to have almost universal efficacy in&#xD;
      a 12 week regimen for genotype 1, and the combination of SOF and Ribavirin (RBV) for&#xD;
      genotypes 2-6 in a 24 week regimen. However, persistence of cryoglobulinemia even after viral&#xD;
      clearance with the newer regimens has also raised the question of whether longer treatment&#xD;
      regimens may be appropriate in the setting of significant extrahepatic disease. Thus, the&#xD;
      timing is right to initiate a trial of all-oral treatment to rigorously evaluate the effect&#xD;
      on extrahepatic disease, and to re-establish the efficacy of antiviral therapy in halting the&#xD;
      direct and indirect role of HCV in driving autoimmune disease and lymphoproliferation. Using&#xD;
      an interferon-sparing regimen to treat patients with HCV-related cryoglobulinemia will help&#xD;
      answer the question as to whether immunomodulating therapy plays a role at all in eradicating&#xD;
      cryoglobulins long-term, and whether antiviral therapy alone is adequate. If the latter,&#xD;
      appreciable morbidity and mortality may be saved in avoiding treating these potentially sick,&#xD;
      often cirrhotic patients, with immunomodulatory therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">July 19, 2019</completion_date>
  <primary_completion_date type="Actual">July 19, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response (SVR)</measure>
    <time_frame>2-4 weeks and 24 weeks after treatment</time_frame>
    <description>Number of participants who attain SVR, ie, cleared HCV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response in Patients With Mixed Cryoglobulinemia (MC)</measure>
    <time_frame>up to 24 weeks after treatment</time_frame>
    <description>Response to medication in patients with MC categorized as either complete response (100% response) vs partial response (50% response).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Cryoglobulinemia</condition>
  <arm_group>
    <arm_group_label>Participant with Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with either Harvoni or Epclusa&#xD;
Harvoni 90mg/400 mg FDC once daily. Subjects will take 1 tablet daily with or without food.&#xD;
Epclusa 400mg/100mg 400mg/100mg FDC once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Harvoni</intervention_name>
    <description>12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis</description>
    <arm_group_label>Participant with Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia</arm_group_label>
    <other_name>Ledipasvir/Sofosbuvir</other_name>
    <other_name>LDV/SOF FDC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epclusa</intervention_name>
    <description>once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.</description>
    <arm_group_label>Participant with Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia</arm_group_label>
    <other_name>Sofosbuvir/Velpatasvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects must meet all of the following inclusion criteria to be eligible for participation&#xD;
        in this study.&#xD;
&#xD;
          1. Willing and able to provide written informed consent&#xD;
&#xD;
          2. Male or female, age ≥18 years&#xD;
&#xD;
          3. HCV RNA ≥ 15 IU/mL at Screening&#xD;
&#xD;
          4. HCV genotype 1&#xD;
&#xD;
          5. Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy&#xD;
&#xD;
          6. Classification as treatment naïve or treatment experienced:&#xD;
&#xD;
               1. Treatment naïve is defined as having never been exposed to approved or&#xD;
                  experimental HCV-specific direct-acting antiviral agents or prior treatment of&#xD;
                  HCV with interferon or ribavirin or DAAs (except for SOF-containing regimens).&#xD;
&#xD;
               2. Treatment experienced is defined as prior treatment failure or relapse to a&#xD;
                  regimen containing interferon either with or without RBV or DAAs (except for&#xD;
                  SOF-containing regimens) that was completed at least 8 weeks prior to&#xD;
                  Baseline/Day 1.&#xD;
&#xD;
             The subject's medical records must include sufficient detail of prior virologic&#xD;
             failure to allow for categorization of prior response, as either:&#xD;
&#xD;
               1. Non-Responder: Subject did not achieve undetectable HCV RNA levels while on&#xD;
                  treatment, or&#xD;
&#xD;
               2. Relapse/Breakthrough: Subject achieved undetectable HCV RNA levels during&#xD;
                  treatment or within 4 weeks of the end of treatment but did not achieve SVR.&#xD;
&#xD;
          7. Cirrhosis determination (approximately 20% of subjects may have cirrhosis) a.&#xD;
             Cirrhosis is defined as any one of the following:&#xD;
&#xD;
             i) Any previous liver biopsy showing cirrhosis (e.g., Metavir score = 4 or Ishak score&#xD;
             ≥5) ii) FibroMeter® score &gt;0.442 or an AST:platelet ratio index (APRI) &gt;2 during&#xD;
             Screening iii) Fibroscan with a result of &gt;12.5 kPa at any time prior to or during&#xD;
             screening.&#xD;
&#xD;
             b. Absence of cirrhosis is defined as any one of the following: i) Liver biopsy within&#xD;
             2 years of Screening showing absence of cirrhosis ii) FibroMeter® score &lt;0.442 or APRI&#xD;
             ≤ 1 performed during Screening iii) Fibroscan with a result of ≤12.5 kPa within 6&#xD;
             months of Baseline/Day 1 Fibroscan results will supersede FibroMeter® /APRI; liver&#xD;
             biopsy results will supersede Fibrotest® /APRI or Fibroscan results and be considered&#xD;
             definitive.&#xD;
&#xD;
          8. Liver imaging (ultrasound, CT scan or MRI) within 6 months of screening is required in&#xD;
             patients with cirrhosis to exclude hepatocellular carcinoma (HCC)&#xD;
&#xD;
          9. Presence of MC vasculitis (please see criteria on the note below).&#xD;
&#xD;
         10. Null or partial response to previous therapies for MC, including corticosteroids,&#xD;
             cytotoxic agents (cyclophosphamide, azathioprine), hydroxychloroquine, methotrexate,&#xD;
             mono- or combination therapy with IFNα/PEG-IFN and ribavirin, and/or CD20 depletion&#xD;
             with Rituximab. a. Patients can be on ongoing treatment with one of the drugs&#xD;
             described above at inclusion unless there is significant DDI.&#xD;
&#xD;
         11. Subjects has the following laboratory parameters at screening:&#xD;
&#xD;
               1. ALT &lt;10 x the upper limit of normal (ULN)&#xD;
&#xD;
               2. AST &lt;10 x ULN&#xD;
&#xD;
               3. Adequate bone marrow function as indicated hematologic parameters listed below&#xD;
                  and/or bone marrow cellularity &gt;60-70% average for age.&#xD;
&#xD;
             i. WBC &gt;1500 /uL ii.Platelets &gt; 50,000/uL&#xD;
&#xD;
             d) Direct bilirubin &gt;2 x ULN e) INR &gt;1.5 x ULN unless subject has known hemophilia or&#xD;
             is stable on an anticoagulant regimen affecting INR&#xD;
&#xD;
         12. Females of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening and a negative urine pregnancy test on Baseline/Day 1 prior to treatment.&#xD;
&#xD;
         13. Male subjects and female subjects of childbearing potential who engage in heterosexual&#xD;
             intercourse must agree to use protocol specified method(s) of contraception.&#xD;
&#xD;
         14. Lactating females must agree to discontinue nursing before the study drug is&#xD;
             administered.&#xD;
&#xD;
         15. Subject must be of generally good health, with the exception of chronic HCV infection,&#xD;
             as determined by the Investigator.&#xD;
&#xD;
         16. Subject must be able to comply with the dosing instructions for study drug&#xD;
             administration and able to complete the study schedule of assessments.&#xD;
&#xD;
        Note: Definition of Mixed Cryoglobulinemia (patients must meet one of the five overlapping&#xD;
        syndromes listed below and the presence of cold-precipitable immune complexes in blood on&#xD;
        two different occasions.&#xD;
&#xD;
          -  Clinical evidence of cryoglobulinemia, overlapping syndromes:&#xD;
&#xD;
               1. Cutaneous vasculitis (Raynaud's phenomenon, purpura, skin ulcers, livedo,&#xD;
                  acrocyanosis)&#xD;
&#xD;
               2. Glomerulonephritis (hypertension, hematuria, nephrotic syndrome)&#xD;
&#xD;
               3. Arthropathy (arthralgias, arthritis)&#xD;
&#xD;
               4. Neuropathy (peripheral and/or central nervous system, distal sensorimotor,&#xD;
                  mononeuritis multiplex)&#xD;
&#xD;
               5. Sicca syndrome (xerostomia, xerophthalmia)&#xD;
&#xD;
                  Other factors that will be assessed / recorded in patients with MC will be:&#xD;
&#xD;
             1. Associated laboratory abnormalities including:&#xD;
&#xD;
          -  Positive HCV serology (recombinant immunoblot assay), viral nucleic acid quantitation&#xD;
             diagnostic for HCV infection, and reflex genotyping.&#xD;
&#xD;
          -  Evidence of glomerulonephritis, including an active urinary sediment, hypoalbuminemia&#xD;
             (albumin &lt;3gm/dL) and/or significant proteinuria (&gt;300mg/day).&#xD;
&#xD;
          -  Abnormal nerve conduction testing. 2. Pathologic evidence of cryoglobulinemia&#xD;
             including:&#xD;
&#xD;
          -  Leukocytoclastic vasculitis.&#xD;
&#xD;
          -  Membranoproliferative glomerulonephritis.&#xD;
&#xD;
          -  Vasculopathy and/or mononuclear cell infiltrates on sural nerve biopsy.&#xD;
&#xD;
          -  Lip biopsy suggestive for Sjogren's syndrome. 3. Laboratory evidence of&#xD;
             cryoglobulinemia including:&#xD;
&#xD;
          -  Characterization of cryoprecipitable material in serum by immunofixation, cryocrit,&#xD;
             and/or quantitation of protein.&#xD;
&#xD;
          -  Associated immunological abnormalities, such as depressed levels of complement,&#xD;
             elevated titers of rheumatoid factor, abnormal immunoglobulin quantitations, and serum&#xD;
             immunofixation carried out on serum and/or isolated cryoglobulins.&#xD;
&#xD;
             4. Laboratory evidence of B-cell clonality, including:&#xD;
&#xD;
          -  IgMk determined by immunofixation of serum and/or cryoglobulin, and kappa excess&#xD;
             &gt;2.65:1 on Free Light Chain (FLC) assay&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Gorevic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med. 2013 Sep 12;369(11):1035-45. doi: 10.1056/NEJMra1208642. Review.</citation>
    <PMID>24024840</PMID>
  </reference>
  <reference>
    <citation>Damoiseaux J. The diagnosis and classification of the cryoglobulinemic syndrome. Autoimmun Rev. 2014 Apr-May;13(4-5):359-62. doi: 10.1016/j.autrev.2014.01.027. Epub 2014 Jan 11. Review.</citation>
    <PMID>24424176</PMID>
  </reference>
  <reference>
    <citation>Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010 Dec;8(12):1017-29. doi: 10.1016/j.cgh.2010.08.026. Epub 2010 Sep 24. Review.</citation>
    <PMID>20870037</PMID>
  </reference>
  <reference>
    <citation>Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, Engels EA. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007 May 9;297(18):2010-7.</citation>
    <PMID>17488966</PMID>
  </reference>
  <reference>
    <citation>Ko HM, Hernandez-Prera JC, Zhu H, Dikman SH, Sidhu HK, Ward SC, Thung SN. Morphologic features of extrahepatic manifestations of hepatitis C virus infection. Clin Dev Immunol. 2012;2012:740138. doi: 10.1155/2012/740138. Epub 2012 Aug 5. Review.</citation>
    <PMID>22919404</PMID>
  </reference>
  <reference>
    <citation>Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hematol Oncol Clin North Am. 1999 Dec;13(6):1315-49. Review.</citation>
    <PMID>10626153</PMID>
  </reference>
  <reference>
    <citation>Gorevic PD. Rheumatoid factor, complement, and mixed cryoglobulinemia. Clin Dev Immunol. 2012;2012:439018. doi: 10.1155/2012/439018. Epub 2012 Aug 26. Review.</citation>
    <PMID>22956968</PMID>
  </reference>
  <reference>
    <citation>Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum. 2002 Dec;32(3):163-73. Review.</citation>
    <PMID>12528081</PMID>
  </reference>
  <reference>
    <citation>Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis. 2014 May;73(5):831-7. doi: 10.1136/annrheumdis-2012-202770. Epub 2013 Apr 20.</citation>
    <PMID>23606708</PMID>
  </reference>
  <reference>
    <citation>Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014 May 15;370(20):1879-88. doi: 10.1056/NEJMoa1402355. Epub 2014 Apr 10.</citation>
    <PMID>24720702</PMID>
  </reference>
  <reference>
    <citation>Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.</citation>
    <PMID>24725239</PMID>
  </reference>
  <reference>
    <citation>Levo Y, Gorevic PD, Kassab HJ, Tobias H, Franklin EC. Liver involvement in the syndrome of mixed cryoglobulinemia. Ann Intern Med. 1977 Sep;87(3):287-92.</citation>
    <PMID>900672</PMID>
  </reference>
  <reference>
    <citation>Diagnosis and treatment of HCV-related mixed cryoglobulinemia over the last decade at a Liver Referral Center Ando, Y, Gorevic, PD, Schiano TD. Hepatology 58 2013 : 1443 abstract</citation>
  </reference>
  <reference>
    <citation>Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic PD. Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol. 2001 Nov;28(11):2466-73.</citation>
    <PMID>11708420</PMID>
  </reference>
  <reference>
    <citation>Levine JW, Gota C, Fessler BJ, Calabrese LH, Cooper SM. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol. 2005 Jun;32(6):1164-7.</citation>
    <PMID>15940780</PMID>
  </reference>
  <reference>
    <citation>Chen AY, Zeremski M, Chauhan R, Jacobson IM, Talal AH, Michalak TI. Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy. PLoS One. 2013 Nov 21;8(11):e80078. doi: 10.1371/journal.pone.0080078. eCollection 2013.</citation>
    <PMID>24278242</PMID>
  </reference>
  <reference>
    <citation>Piluso A, Giannini C, Fognani E, Gragnani L, Caini P, Monti M, Petrarca A, Ranieri J, Urraro T, Triboli E, Laffi G, Zignego AL. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. J Viral Hepat. 2013 Apr;20(4):e107-14. doi: 10.1111/jvh.12017. Epub 2012 Dec 4.</citation>
    <PMID>23490377</PMID>
  </reference>
  <reference>
    <citation>Russi S, Sansonno D, Mariggiò MA, Vinella A, Pavone F, Lauletta G, Sansonno S, Dammacco F. Assessment of total hepatitis C virus (HCV) core protein in HCV-related mixed cryoglobulinemia. Arthritis Res Ther. 2014 Mar 18;16(2):R73. doi: 10.1186/ar4513.</citation>
    <PMID>24636026</PMID>
  </reference>
  <reference>
    <citation>Sansonno D, Tucci FA, Ghebrehiwet B, Lauletta G, Peerschke EI, Conteduca V, Russi S, Gatti P, Sansonno L, Dammacco F. Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage. J Immunol. 2009 Nov 1;183(9):6013-20. doi: 10.4049/jimmunol.0902038. Epub 2009 Oct 14.</citation>
    <PMID>19828637</PMID>
  </reference>
  <reference>
    <citation>Quartuccio L, Isola M, Corazza L, Ramos-Casals M, Retamozo S, Ragab GM, Zoheir MN, El-Menyawi MA, Salem MN, Sansonno D, Ferraccioli G, Gremese E, Tzioufas A, Voulgarelis M, Vassilopoulos D, Scarpato S, Pipitone N, Salvarani C, Guillevin L, Terrier B, Cacoub P, Filippini D, Saccardo F, Gabrielli A, Fraticelli P, Sebastiani M, Tomsic M, Tavoni A, Mazzaro C, Pioltelli P, Nishimoto N, Scaini P, Zignego AL, Ferri C, Monti G, Pietrogrande M, Bombardieri S, Galli M, De Vita S. Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology (Oxford). 2014 Dec;53(12):2209-13. doi: 10.1093/rheumatology/keu271. Epub 2014 Jul 3.</citation>
    <PMID>24994905</PMID>
  </reference>
  <reference>
    <citation>Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727-35.</citation>
    <PMID>7779114</PMID>
  </reference>
  <reference>
    <citation>Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, Specks U, Allen NB, Davis JC, Spiera RF, Calabrese LH, Wigley FM, Maiden N, Valente RM, Niles JL, Fye KH, McCune JW, St Clair EW, Luqmani RA; International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001 Apr;44(4):912-20.</citation>
    <PMID>11318006</PMID>
  </reference>
  <reference>
    <citation>Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol. 2014 Jun 28;20(24):7544-54. doi: 10.3748/wjg.v20.i24.7544. Review.</citation>
    <PMID>24976695</PMID>
  </reference>
  <reference>
    <citation>Benstead TJ, Chalk CH, Parks NE. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection. Cochrane Database Syst Rev. 2014 Dec 20;(12):CD010404. doi: 10.1002/14651858.CD010404.pub2. Review.</citation>
    <PMID>25525951</PMID>
  </reference>
  <reference>
    <citation>Gragnani L, Fognani E, Piluso A, Boldrini B, Urraro T, Fabbrizzi A, Stasi C, Ranieri J, Monti M, Arena U, Iannacone C, Laffi G, Zignego AL; MaSVE Study Group. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology. 2015 Apr;61(4):1145-53. doi: 10.1002/hep.27623. Epub 2015 Feb 10.</citation>
    <PMID>25431357</PMID>
  </reference>
  <reference>
    <citation>Foulks GN, Forstot SL, Donshik PC, Forstot JZ, Goldstein MH, Lemp MA, Nelson JD, Nichols KK, Pflugfelder SC, Tanzer JM, Asbell P, Hammitt K, Jacobs DS. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf. 2015 Apr;13(2):118-32. doi: 10.1016/j.jtos.2014.12.001. Epub 2015 Jan 15. Review.</citation>
    <PMID>25881996</PMID>
  </reference>
  <reference>
    <citation>Delli K, Spijkervet FK, Kroese FG, Bootsma H, Vissink A. Xerostomia. Monogr Oral Sci. 2014;24:109-25. doi: 10.1159/000358792. Epub 2014 May 23. Review.</citation>
    <PMID>24862599</PMID>
  </reference>
  <reference>
    <citation>Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D; EULAR; ACR. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum. 2008 Oct 15;59(10):1371-7. doi: 10.1002/art.24123.</citation>
    <PMID>18821648</PMID>
  </reference>
  <reference>
    <citation>Gorevic, PD; &quot;Mixed Cryoglobulinemia Cross-reactive Idiotypes: Structural and Clinical Significance&quot; Cryoglobulinemia &amp; Hepatitis C Infection, Dammacco, F (Editor); Springer Verlag, 2012, p. 99-107.</citation>
  </reference>
  <reference>
    <citation>Gorevic PD and Galanakis DK;</citation>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 3, 2016</study_first_submitted>
  <study_first_submitted_qc>July 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <results_first_submitted>October 5, 2020</results_first_submitted>
  <results_first_submitted_qc>November 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2020</results_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Peter Gorevic</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Cryoglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Cryoglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02825212/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were self referred after discussion with their physicians, enrolled sequentially over a two year period (2016-2018)</recruitment_details>
      <pre_assignment_details>Long recruitment, with part of the problem of finding patients not already on antivirals. The original protocol was for Harvoni, which had been specifically licensed for Hepatitis C Virus genotype 1. Protocol was modified after discussion with Gilead with the licensing of Epclusa, which is active for other genotypes, specifically to be able to include two patients with genotype 2 thus enabling the study to reach full enrollment. Study objective is not to compare medications.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pts With Hep C Virus Infection-Related Cryoglobulinemia</title>
          <description>Participants with Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia who were treated with antivirals.&#xD;
Antivirals were either Harvoni or Epclusa. Ledipasvir/Sofosbuvir (Harvoni) 90mg/400 mg FDC once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced subjects) or 24 weeks (treatment experienced subjects with compensated cirrhosis) for genotype 1 .&#xD;
Sofosbuvir/Velpatasvir (Epclusa) 400mg/100mg 400mg/100mg FDC once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pts With Hep C Virus Infection-Related Cryoglobulinemia</title>
          <description>Participants with Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia who were treated with antivirals.&#xD;
Antivirals were either Harvoni or Epclusa. Ledipasvir/Sofosbuvir (Harvoni) 90mg/400 mg FDC once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced subjects) or 24 weeks (treatment experienced subjects with compensated cirrhosis) for genotype 1 .&#xD;
Sofosbuvir/Velpatasvir (Epclusa) 400mg/100mg 400mg/100mg FDC once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" spread="14.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years Since HCV Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.1" spread="12.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment Naive</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cirrhosis</title>
          <description>diagnosed by imaging or biopsy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AST levels</title>
          <description>normal is &lt;40 U/L</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.7" spread="99.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelets level</title>
          <description>normal 150-450K/uL</description>
          <units>K/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192.7" spread="73.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV genotype</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bilirubin</title>
          <description>normal &lt;1.2 mg/dL</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.93" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Viral Count</title>
          <units>IU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.98" spread="136.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepa Score for Fibrosis</title>
          <description>Quantitative results of 6 biochemical tests analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) for liver fibrosis (METAVIR F0-F4).&#xD;
Fibrosis scoring&#xD;
&lt;0.21 = Stage F0 - No fibrosis&#xD;
0.21 - 0.27 = Stage F0 - F1&#xD;
0.27 - 0.31 = Stage F1 - Portal fibrosis&#xD;
0.31 - 0.48 = Stage F1 - F2&#xD;
0.48 - 0.58 = Stage F2 - Bridging fibrosis with few septa&#xD;
0.58 - 0.72 = Stage F3 - Bridging fibrosis with many septa&#xD;
0.72 - 0.74 = Stage F3 - F4&#xD;
&gt;0.74 = Stage F4 - Cirrhosis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>F0-F1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F1-F2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F2-F4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Virologic Response (SVR)</title>
        <description>Number of participants who attain SVR, ie, cleared HCV</description>
        <time_frame>2-4 weeks and 24 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pts With Hep C Virus Infection-Related Cryoglobulinemia</title>
            <description>Participants with Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia who were treated with antivirals.&#xD;
Antivirals were either Harvoni or Epclusa. Ledipasvir/Sofosbuvir (Harvoni) 90mg/400 mg FDC once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced subjects) or 24 weeks (treatment experienced subjects with compensated cirrhosis) for genotype 1 .&#xD;
Sofosbuvir/Velpatasvir (Epclusa) 400mg/100mg 400mg/100mg FDC once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response (SVR)</title>
          <description>Number of participants who attain SVR, ie, cleared HCV</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-4 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Response in Patients With Mixed Cryoglobulinemia (MC)</title>
        <description>Response to medication in patients with MC categorized as either complete response (100% response) vs partial response (50% response).</description>
        <time_frame>up to 24 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pts With Hep C Virus Infection-Related Cryoglobulinemia</title>
            <description>Participants with Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia who were treated with antivirals.&#xD;
Antivirals were either Harvoni or Epclusa. Ledipasvir/Sofosbuvir (Harvoni) 90mg/400 mg FDC once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced subjects) or 24 weeks (treatment experienced subjects with compensated cirrhosis) for genotype 1 .&#xD;
Sofosbuvir/Velpatasvir (Epclusa) 400mg/100mg 400mg/100mg FDC once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Response in Patients With Mixed Cryoglobulinemia (MC)</title>
          <description>Response to medication in patients with MC categorized as either complete response (100% response) vs partial response (50% response).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 24 weeks after treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pts With Hep C Virus Infection-Related Cryoglobulinemia</title>
          <description>Participants with Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia who were treated with antivirals.&#xD;
Antivirals were either Harvoni or Epclusa. Ledipasvir/Sofosbuvir (Harvoni) 90mg/400 mg FDC once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced subjects) or 24 weeks (treatment experienced subjects with compensated cirrhosis) for genotype 1 .&#xD;
Sofosbuvir/Velpatasvir (Epclusa) 400mg/100mg 400mg/100mg FDC once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increased fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency and/or dysuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Peter D. Gorevic</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-0968</phone>
      <email>peter.gorevic@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

